Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

Fig. 2

Evaluation of efficacy and tumor responses. a, Maximum change in tumor size from baseline. Seventeen of 20 patients obtained PR based on the percentage changes of the sum of the maximum diameter of the tumor lesion (range − 28% to − 100%); b, the change of lesion diameters over time from baseline; each line represents the changes in one patient; c, PFS Kaplan-Meier curve; d, OS Kaplan-Meier curve; e, the objective response rate in low and high TMB groups. OS, overall survival; PFS, progression-free survival; PR partial response; SD, stable disease; TMB, tumor mutation burden

Back to article page